Axsome Therapeutics, Inc.
General ticker "AXSM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $5.5B (TTM average)
Axsome Therapeutics, Inc. follows the US Stock Market performance with the rate: 45.7%.
Estimated limits based on current volatility of 1.7%: low 159.27$, high 164.80$
Factors to consider:
- Total employees count: 683 as of 2024
- US accounted for 98.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Significant losses, Profitability concerns, Internal control weaknesses, Dependence on key products, Regulatory and compliance
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [100.60$, 205.84$]
- 2026-12-31 to 2027-12-31 estimated range: [81.07$, 172.84$]
Financial Metrics affecting the AXSM estimates:
- Negative: with PPE of -45.8 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.22 <= 0.01
- Positive: Inventory ratio change, % of 0.27 <= 0.80
- Negative: Shareholder equity ratio, % of 12.80 <= 19.40
- Positive: Interest expense per share per price, % of 0.09 <= 0.73
- Positive: Investing cash flow per share per price, % of -0.01 > -0.63
- Negative: negative Net income
Short-term AXSM quotes
Long-term AXSM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $270.60MM | $385.69MM | $638.50MM |
| Operating Expenses | $502.43MM | $666.25MM | $807.73MM |
| Operating Income | $-231.82MM | $-280.56MM | $-169.24MM |
| Non-Operating Income | $-6.45MM | $-6.57MM | $-14.47MM |
| Interest Expense | $0.00MM | $0.00MM | $6.56MM |
| R&D Expense | $97.94MM | $187.08MM | $183.28MM |
| Income(Loss) | $-238.28MM | $-287.13MM | $-183.70MM |
| Taxes | $0.96MM | $0.09MM | $-0.53MM |
| Profit(Loss)* | $-239.24MM | $-287.22MM | $-183.17MM |
| Stockholders Equity | $190.98MM | $57.02MM | $88.30MM |
| Inventory | $15.13MM | $15.73MM | $27.94MM |
| Assets | $588.24MM | $568.50MM | $689.80MM |
| Operating Cash Flow | $-145.08MM | $-128.41MM | $-93.41MM |
| Capital expenditure | $0.58MM | $0.27MM | $0.00MM |
| Investing Cash Flow | $-0.58MM | $-0.27MM | $-0.48MM |
| Financing Cash Flow | $331.01MM | $57.84MM | $101.47MM |
| Earnings Per Share** | $-5.27 | $-5.99 | $-3.68 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.